Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. | After a ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Bill Anderson, CEO and Board Chairman of Bayer AG, speaks with reporters on Friday, Sept. 13, 2024, at the St. Louis Post ...

The campaign's lobbyist donors work to influence the federal government on behalf of companies including Boeing, Walmart, ...

The global Animal Antibacterial and Antibiotics Market is projected to grow from approximately USD 4.9 billion in 2024 to ...

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdatifan leading the way. See why I rate RCUS ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...